GlassScriptPhysician profile
Maheswar Rao
NPI 1306812326
$2,924.28
in general payments reported to CMS, 2019-2025
29 companies · $400 in 2025
The $400 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $495 · 2020: $389 · 2021: $489 · 2022: $588 · 2023: $380 · 2024: $182 · 2025: $400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $962.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $962.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $666.45 | 2019-2025 | |
| Janssen Biotech, INC. | $376.89 | 2019-2025 | Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $286.91 | 2019-2025 | Xifaxan |
| Pfizer INC. | $281.01 | 2019-2025 | |
| Celgene Corporation | $187.57 | 2021-2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $159.27 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $122.76 | 2019-2022 | |
| Boston Scientific Corporation | $111.14 | 2022-2024 | Orca |
| Fujifilm Healthcare Americas Corporation | $96.64 | 2023 | Utaswako Afp-L3 |
| Mallinckrodt Hospital Products INC. | $93.48 | 2022-2024 | Terlivaz |
| Madrigal Pharmaceuticals | $82.56 | 2025 | Rezdiffra |
| Gilead Sciences, INC. | $50.88 | 2022-2025 | |
| Daiichi Sankyo INC. | $48.21 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $43.99 | 2025 | Iqirvo |
| Allergan, INC. | $42.10 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $36.85 | 2023 | Ibsrela |
| Qol Medical, LLC | $35.63 | 2019-2022 | |
| Romark Laboratories, Lc | $29.50 | 2020 | |
| Ucb, INC. | $27.97 | 2019 | |
| Aimmune Therapeutics, INC. | $26.07 | 2025 | Vowst |
| Olympus America INC. | $19.83 | 2019 | |
| Nestle Healthcare Nutrition INC. | $18.69 | 2021 | |
| Amgen INC. | $16.80 | 2022 | |
| Celltrion USA INC. | $14.17 | 2025 | Vegzelma |
| Redhill Biopharma INC. | $12.94 | 2022 | |
| Intercept Pharmaceuticals, INC. | $12.07 | 2022 | |
| Shionogi INC | $12.00 | 2019 | |
| Merck Sharp & Dohme LLC | $11.90 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$65,805.23 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maheswar Rao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.